Statins, systemic inflammation and risk of death in COPD: the Rotterdam study.
Pulm Pharmacol Ther
; 26(2): 212-7, 2013 Apr.
Article
en En
| MEDLINE
| ID: mdl-23142156
ABSTRACT
BACKGROUND:
Studies suggest that statins decrease mortality in COPD patients but it is unknown which patients might benefit most.OBJECTIVES:
We investigated whether statins were associated with reduced mortality in COPD patients and whether effects differed according to baseline high-sensitivity C-reactive protein (hsCRP) concentration, a marker of systemic inflammation.METHODS:
This nested case-control study was part of the Rotterdam Study, a prospective population-based cohort study among 7983 subjects ≥ 55 years. Using automated pharmacy records, we evaluated statin use of 363 cases (COPD patients who died during follow-up of 17 years) with 2345 age and sex matched controls (COPD patients who survived the follow-up period of the index case).RESULTS:
Compared to never use, long-term statin use (>2 years) was associated with a 39% decreased risk of death in COPD patients. Stratified according to the level of systemic inflammation, long-term statin use was associated with a 78% reduced mortality if hsCRP level > 3 mg/L, versus a non significant 21% reduced mortality if hsCRP level ≤ 3 mg/L.CONCLUSIONS:
Statin use is associated with a beneficial effect on all-cause mortality in COPD, depending on the baseline level of systemic inflammation.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Inhibidores de Hidroximetilglutaril-CoA Reductasas
/
Enfermedad Pulmonar Obstructiva Crónica
/
Inflamación
Tipo de estudio:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Risk_factors_studies
Límite:
Aged
/
Aged80
/
Female
/
Humans
/
Male
Idioma:
En
Año:
2013
Tipo del documento:
Article